Brief corporate introduction to Molecular Health, Heidelberg (Q2-2019). Molecular Health is a data science-focused artificial intelligence computing company dedicated to big-data capture, curation, integration and analytics to enable precision medicine and generate novel and actionable insights on drug outcomes for stakeholders across the healthcare ecosystem. For more information, visit www.molecularhealth.com

1. 1
April 2019
Molecular Health
Company introduction

2. © 2018 Molecular Health GmbH. All rights reserved. Confidential.
2© 2018 Molecular Health GmbH. All rights reserved. Confidential.
C O M P A N Y O V E R V I E W
Molecular Health
Molecular Health is uniquely positioned to
enable precision medicine
€150mn
Invested capital in
total, since 2004
10+ years
Investment in deep in-silico
research and development
Two hubs
Heidelberg
Boston
105
Employees
89%
Academics
42%
PhDs/MDs
BOSTON HEIDELBERG
Core capabilities
• Capturing
• Curation
• Integration
• Contextualization
• Referencing
• Interpretation
• Analytics
Current, complete,
comprehensive
biomedical knowledge
Physicians
Hospitals
Regulators
Financial
Industry
Pharma Payers
Customers and partners

3. © 2018 Molecular Health GmbH. All rights reserved. Confidential.
3© 2018 Molecular Health GmbH. All rights reserved. Confidential.
T H R E E P R O M I S E S O F P R E C I S I O N M E D I C I N E
AI-aided Treatment Decisions
based on individual molecular make up of
disease and referenced vs. world’s
biomedicine evidence
Predict Real World Outcomes
during clinical development, leveraging RCT
& RWE data to de-risk clinical trials
AI-driven prediction of PTS
utilising the whole data universe in the domain:
clinical, molecular, on disease and drug
1
2
3
Data challenges
• Scattered data
• Data sources differ in quality, scope,
terminologies, completeness
AI/machine learning challenges
• Genomic-analysis software require integrated,
cleaned and harmonised clinico-molecular data
• Mix machine and human intelligence is needed
to assure quality
Market readiness challenges
• FDA endorsement of genomic profiling &
biomarker/ CDx reimbursement
• Slow clinical adoption
Our focus

4. © 2018 Molecular Health GmbH. All rights reserved. Confidential.
4
M H T E C H N O L O G Y & C A P A B I L I T I E S
Data & AI challenges need highly specialized technology to allow for
clinico-molecular interconnectivity
 Disease pathways
 Drugs universe/ MoA
 Scientific literature
 Clinical trials
 Patient longitudinal records
 Genetic variants
 De-biased reference
genomes
 Variant interpretation/
functional impact
 Drug – Target relations
 Biomarkers

5. © 2018 Molecular Health GmbH. All rights reserved. Confidential.
5
T E C H N O L O G Y V A L I D A T I O N
We built Dataome to answer questions asked by;
Physicians
What is the optimal
treatment for my
patients?
Hospitals
How can we use personalized
medicine and leverage the
value of our EMR data?
Pharma & Biotech
How can we make better
decisions across the Pharma
Value Chain?
Regulators
How can we optimize
patient safety and enhance
Pharma Co accountability?
Financial Industry
How can we de-risk our
Pharma/Biotech
investments?
Laboratories
What is the optimal
treatment for my patients?

6. © 2018 Molecular Health GmbH. All rights reserved. Confidential.
6
T E C H N O L O G Y V A L I D A T I O N
Dataome Technology Platform: Data capture, integration and analysis
DATAOME KNOWLEDGEBASE
Public and private clinico-
molecular data
Structured and
unstructured data
Medical Literature
RCTs
Real world data
Physicians
Hospitals
Laboratories
Genome-guided treatment decision support
Regulators
Molecular analysis of adverse clinical outcomes
Pharma & Biotech
Clinico-molecular drug development analytics
Pharma & Biotech
Financial Industry
Predict LOS of drug development programs

7. © 2018 Molecular Health GmbH. All rights reserved. Confidential.
7
T E C H N O L O G Y V A L I D A T I O N
Sample of scientific publications validating our technology and expertise
DRUG SAFETY
2016/2018
DRUG COMBINATION
& REPURPOSING
2013
BIOMAKER DISCOVERY
2015
MOLECULAR ANALYSIS
OF DISEASE PATHWAYS
2015
BIOINFORMATICS
2017
CLINICAL CLASSIFIER
2016
Publications available on request